敗血症診断市場：検査タイプ、技術、製品、方法、病原体、エンドユーザー別-世界予測2025-2030年

敗血症診断市場は、2023年に5億5,686万米ドルと評価され、2024年には6億1,180万米ドルに達すると予測され、CAGR 9.98%で成長し、2030年には10億8,417万米ドルに達すると予測されています。

敗血症診断薬はヘルスケアにおいて重要な役割を担っており、敗血症の迅速な特定と管理を行うことで死亡率を低下させ、患者の転帰を改善します。その必要性は、敗血症の生命を脅かす性質から生じ、タイムリーな治療を開始するために迅速かつ正確な診断が必要となります。アプリケーションには主に病院、診断研究所、診療所が含まれ、そこでは敗血症の病原体やバイオマーカーを検出するために分子診断、イムノアッセイ、マイクロアレイなどの検査が利用されます。エンドユースセグメントには、ヘルスケアプロバイダー、統合医療提供ネットワーク、研究施設などが含まれます。市場成長の原動力は、敗血症の発生率の上昇、診断技術の進歩、早期診断に関するヘルスケア専門家の意識の高まりです。AIベースの診断ツールやpoint-of-care検査機器などのイノベーションは、成長の大きな機会をもたらします。さらに、敗血症を抑制するための政府の取り組みや、特に新興国におけるヘルスケアインフラへの投資も、市場の見通しを強化しています。機会を捉えるための推奨事項には、技術統合のための協力関係の促進や、研究開発による精密診断の能力拡大が含まれます。しかし、高度な診断システムの高価格、標準化されたプロトコルの欠如、診断を複雑にする敗血症の複雑性などの課題に直面しています。加えて、規制上の課題や償還の問題が採用率を制限しています。このような課題を克服するためには、手頃な価格で利用しやすい診断ソリューションに焦点を当て、教育を通じて認知度を高めることが大きな成果をもたらす可能性があります。診断におけるバイオインフォマティクスと機械学習は、診断の精度と効率を向上させる可能性のある研究手段として注目されています。全体として、敗血症診断市場はダイナミックな技術進化と危機的な需要を特徴としており、イノベーション主導の成長の余地が十分にある一方で、より幅広いアクセシビリティのためにコストと複雑性の障壁に対処する必要があります。

市場力学：急速に進化する敗血症診断市場の主要市場インサイトを公開

敗血症診断市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 敗血症の発生率と有病率の増加
  • 病院由来感染症の増加
  • 高度な診断ソリューション技術の開発
• 市場抑制要因
  • 資本集約的な自動診断サービスと償還の乏しい状況
• 市場機会
  • 世界の迅速診断の開発台頭
  • 敗血症診断のための新規バイオマーカーの開発
• 市場の課題
  • 手順に対する認識と標準プロトコルの欠如

ポーターのファイブフォース：敗血症診断市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：敗血症診断市場における外部からの影響の把握

外部マクロ環境要因は、敗血症診断市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析敗血症診断市場における競合情勢の把握

敗血症診断市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス敗血症診断市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、敗血症診断市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨敗血症診断市場における成功への道筋を描く

敗血症診断市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 敗血症の発生率と有病率の増加
    • 院内感染の増加
    • 技術開発高度な診断ソリューション
  • 抑制要因
    • 資本集約型の自動診断サービスと償還不足の状況
  • 機会
    • 世界中で急速に開発する迅速診断法
    • 敗血症診断のための新規バイオマーカーの開発
  • 課題
    • 手順に関する認識と標準プロトコルの欠如
• 市場セグメンテーション分析
  • 検査の種類：敗血症診断のためのPoC検査ソリューションの利用増加
  • エンドユーザー：病理学およびリファレンスラボにおける高度な敗血症診断ソリューションの新たな利用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 敗血症診断市場テストの種類別

• 臨床検査
• PoCテスト

第7章 敗血症診断市場：技術別

• フローサイトメトリー
• 免疫測定
• 微生物学
• 分子診断

第8章 敗血症診断市場：製品別

• アッセイキットおよび試薬
• 血液培養培地
• 機器
• ソフトウェア

第9章 敗血症診断市場：方法別

• 自動診断
• 従来の診断

第10章 敗血症診断市場病原体別

• 細菌性敗血症
  • グラム陰性細菌
  • グラム陽性細菌
• 真菌性敗血症

第11章 敗血症診断市場：エンドユーザー別

• 病院
• 病理学および参照検査室
• 調査室および学術機関

第12章 南北アメリカの敗血症診断市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域の敗血症診断市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカの敗血症診断市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • Prenosis社によるFDA認可AIツールの発表
  • プレシンプトム・ヘルスによる革新的なAIを活用した敗血症の早期検出が150万ポンドの資金を確保
  • Cytovale、シリーズC資金調達で8,400万米ドルの戦略的前進
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alifax S.r.l.
• Beckman Coulter, Inc.
• Becton, Dickinson and Company
• bioMerieux SA
• Boditech Med Inc.
• Bruker Corporation
• CytoSorbents Corporation
• DiaSorin S.p.A.
• EKF Diagnostics
• F. Hoffmann-La Roche AG
• Immunexpress Inc.
• Koninklijke Philips N.V.
• McKesson Corporation
• Merck KGaA
• Molzym GmbH & Co. KG
• Nanomix Inc.
• Oracle Corporation
• QIAGEN N.V.
• Response Biomedical Corporation
• Seegene Inc.
• Siemens Healthineers
• T2 Biosystems
• Thermo Fisher Scientific, Inc.
• Wolters Kluwer N.V.

LIST OF FIGURES

• FIGURE 1. SEPSIS DIAGNOSTIC MARKET RESEARCH PROCESS
• FIGURE 2. SEPSIS DIAGNOSTIC MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. SEPSIS DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. SEPSIS DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SEPSIS DIAGNOSTIC MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SEPSIS DIAGNOSTIC MARKET DYNAMICS
• TABLE 7. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY POC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY MICROBIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY ASSAY KITS AND REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY BLOOD CULTURE MEDIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY AUTOMATED DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY CONVENTIONAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY GRAM-NEGATIVE BACTERIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY GRAM-POSITIVE BACTERIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY FUNGAL SEPSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL SEPSIS DIAGNOSTIC MARKET SIZE, BY RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 59. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 60. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 61. CANADA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 65. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES SEPSIS DIAGNOSTIC MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 80. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 85. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 86. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 87. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 93. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 94. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 95. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 96. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 97. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 98. CHINA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 100. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 102. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 103. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 104. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 105. INDIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 137. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 144. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 149. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 150. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 151. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 156. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 157. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 158. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 163. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 164. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 177. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 178. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 179. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 185. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 187. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 192. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 193. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 194. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 199. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 200. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 201. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 205. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 206. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 207. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 208. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 213. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 214. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 220. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 222. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 223. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 224. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 225. ITALY SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 227. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 229. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 233. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 234. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 235. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 236. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 241. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 242. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 243. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 247. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 248. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 249. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 250. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 251. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 252. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 253. POLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 254. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 255. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 256. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 257. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 258. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 259. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 260. QATAR SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 261. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 262. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 263. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 264. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 269. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 270. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 271. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 275. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 276. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 277. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 278. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 282. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 283. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 284. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 285. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 289. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 290. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 291. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 292. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 296. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 297. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 298. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 299. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 303. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 304. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 305. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 306. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 310. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 311. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 312. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 313. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 317. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2030 (USD MILLION)
• TABLE 318. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 319. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 320. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY PATHOGEN, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY BACTERIAL SEPSIS, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM SEPSIS DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 324. SEPSIS DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 325. SEPSIS DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2023

The Sepsis Diagnostic Market was valued at USD 556.86 million in 2023, expected to reach USD 611.80 million in 2024, and is projected to grow at a CAGR of 9.98%, to USD 1,084.17 million by 2030.

Sepsis diagnostics play a critical role in healthcare, providing rapid identification and management of sepsis to reduce mortality rates and improve patient outcomes. The necessity arises from sepsis's life-threatening nature, requiring swift and accurate diagnosis to initiate timely treatment. Applications primarily include hospitals, diagnostic laboratories, and clinics, where tests like molecular diagnostics, immunoassays, and microarrays are utilized to detect sepsis pathogens and biomarkers. End-use segments encompass healthcare providers, integrated delivery networks, and research facilities. Market growth is driven by the rising incidence of sepsis, advances in diagnostic technology, and increased awareness among healthcare professionals about early diagnosis. Innovations such as AI-based diagnostic tools and point-of-care testing devices present substantial opportunities for growth. Furthermore, government initiatives to curb sepsis and investments in healthcare infrastructure, especially in emerging economies, also bolster market prospects. Recommendations to seize opportunities include fostering collaborations for technology integration and expanding capabilities in precision diagnostics through R&D. However, market growth faces challenges such as the high cost of advanced diagnostic systems, lack of standardized protocols, and the complexity of sepsis as a condition, which complicates diagnosis. Additionally, regulatory challenges and reimbursement issues limit adoption rates. To navigate these challenges, focusing on affordable, accessible diagnostic solutions and enhancing awareness through education can yield significant dividends. Bioinformatics and machine learning in diagnostics stand out as potential research avenues, offering prospects for improved diagnostic accuracy and efficiency. Overall, the sepsis diagnostic market is characterized by dynamic technological evolution and a critical demand, presenting ample scope for innovation-driven growth while necessitating addressing cost and complexity barriers for broader accessibility.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sepsis Diagnostic Market

The Sepsis Diagnostic Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Incidence and Prevalence of Sepsis
  • Growing Occurrence of Hospital Derived Infections
  • Development of Technology Advanced Diagnostic Solutions
• Market Restraints
  • Capital Intensive Automated Diagnostic Services and Dearth of Reimbursement Situations
• Market Opportunities
  • Emerging Development of Rapid Diagnostics Globally
  • Development of Novel Biomarkers for Sepsis Diagnostics
• Market Challenges
  • Lack of Awareness and Standard Protocols for the Procedure

Porter's Five Forces: A Strategic Tool for Navigating the Sepsis Diagnostic Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sepsis Diagnostic Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sepsis Diagnostic Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sepsis Diagnostic Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sepsis Diagnostic Market

A detailed market share analysis in the Sepsis Diagnostic Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sepsis Diagnostic Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sepsis Diagnostic Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sepsis Diagnostic Market

A strategic analysis of the Sepsis Diagnostic Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sepsis Diagnostic Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alifax S.r.l., Beckman Coulter, Inc., Becton, Dickinson and Company, bioMerieux SA, Boditech Med Inc., Bruker Corporation, CytoSorbents Corporation, DiaSorin S.p.A., EKF Diagnostics, F. Hoffmann-La Roche AG, Immunexpress Inc., Koninklijke Philips N.V., McKesson Corporation, Merck KGaA, Molzym GmbH & Co. KG, Nanomix Inc., Oracle Corporation, QIAGEN N.V., Response Biomedical Corporation, Seegene Inc., Siemens Healthineers, T2 Biosystems, Thermo Fisher Scientific, Inc., and Wolters Kluwer N.V..

Market Segmentation & Coverage

This research report categorizes the Sepsis Diagnostic Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Testing Type, market is studied across Laboratory Testing and PoC Testing.
• Based on Technology, market is studied across Flow Cytometry, Immunoassays, Microbiology, and Molecular Diagnostics.
• Based on Product, market is studied across Assay Kits and Reagents, Blood Culture Media, Instruments, and Software.
• Based on Method, market is studied across Automated Diagnostics and Conventional Diagnostics.
• Based on Pathogen, market is studied across Bacterial Sepsis and Fungal Sepsis. The Bacterial Sepsis is further studied across Gram-Negative Bacteria and Gram-Positive Bacteria.
• Based on End-user, market is studied across Hospitals, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Incidence and Prevalence of Sepsis
    • 5.1.1.2. Growing Occurrence of Hospital Derived Infections
    • 5.1.1.3. Development of Technology Advanced Diagnostic Solutions
  • 5.1.2. Restraints
    • 5.1.2.1. Capital Intensive Automated Diagnostic Services and Dearth of Reimbursement Situations
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging Development of Rapid Diagnostics Globally
    • 5.1.3.2. Development of Novel Biomarkers for Sepsis Diagnostics
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of Awareness and Standard Protocols for the Procedure
• 5.2. Market Segmentation Analysis
  • 5.2.1. Testing Type: Increasing usage of PoC testing solutions for sepsis diagnostics
  • 5.2.2. End-user: Emerging use of advanced sepsis diagnostics solutions in pathology and reference laboratories
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Sepsis Diagnostic Market, by Testing Type

• 6.1. Introduction
• 6.2. Laboratory Testing
• 6.3. PoC Testing

7. Sepsis Diagnostic Market, by Technology

• 7.1. Introduction
• 7.2. Flow Cytometry
• 7.3. Immunoassays
• 7.4. Microbiology
• 7.5. Molecular Diagnostics

8. Sepsis Diagnostic Market, by Product

• 8.1. Introduction
• 8.2. Assay Kits and Reagents
• 8.3. Blood Culture Media
• 8.4. Instruments
• 8.5. Software

9. Sepsis Diagnostic Market, by Method

• 9.1. Introduction
• 9.2. Automated Diagnostics
• 9.3. Conventional Diagnostics

10. Sepsis Diagnostic Market, by Pathogen

• 10.1. Introduction
• 10.2. Bacterial Sepsis
  • 10.2.1. Gram-Negative Bacteria
  • 10.2.2. Gram-Positive Bacteria
• 10.3. Fungal Sepsis

11. Sepsis Diagnostic Market, by End-user

• 11.1. Introduction
• 11.2. Hospitals
• 11.3. Pathology & Reference Laboratories
• 11.4. Research Laboratories & Academic Institutes

12. Americas Sepsis Diagnostic Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific Sepsis Diagnostic Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa Sepsis Diagnostic Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
  • 15.3.1. Unveiling of FDA-Authorized AI Tool by Prenosis, Inc.
  • 15.3.2. Innovative AI-Powered Early Detection of Sepsis by Presymptom Health Secures GBP 1.5 Million in Funding
  • 15.3.3. Cytovale's Strategic Advancement with USD 84 Million Series C Funding
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alifax S.r.l.
• 3. Beckman Coulter, Inc.
• 4. Becton, Dickinson and Company
• 5. bioMerieux SA
• 6. Boditech Med Inc.
• 7. Bruker Corporation
• 8. CytoSorbents Corporation
• 9. DiaSorin S.p.A.
• 10. EKF Diagnostics
• 11. F. Hoffmann-La Roche AG
• 12. Immunexpress Inc.
• 13. Koninklijke Philips N.V.
• 14. McKesson Corporation
• 15. Merck KGaA
• 16. Molzym GmbH & Co. KG
• 17. Nanomix Inc.
• 18. Oracle Corporation
• 19. QIAGEN N.V.
• 20. Response Biomedical Corporation
• 21. Seegene Inc.
• 22. Siemens Healthineers
• 23. T2 Biosystems
• 24. Thermo Fisher Scientific, Inc.
• 25. Wolters Kluwer N.V.